Apomorphine injections: Predictors of initial common adverse events and long term tolerability

Parkinsonism and Related Disorders

Volumn 18, Issue 5, 2012, Pages 619-622

  Ondo, William G ^a   Hunter, Christine ^a   Ferrara, Joseph M ^b   Mostile, Giovanni ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Adverse events; Apomorphine; Parkinson's disease; Tolerability

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; TRIMETHOBENZAMIDE;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; DEMOGRAPHY; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG TOLERABILITY; DYSKINESIA; EDEMA; FEMALE; FLUSHING; HALLUCINATION; HEADACHE; HUMAN; INJECTION SITE REACTION; MALE; MEDICAL HISTORY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHINORRHEA; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TACHYPNEA; THORAX PAIN; TREATMENT DURATION; VISUAL ANALOG SCALE; YAWNING;

AGED; ANTIPARKINSON AGENTS; APOMORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; FEMALE; HUMANS; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; TIME FACTORS;

EID: 84861185325     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.01.001     Document Type: Article

References (7)

1. Garcia Ruiz P.J., Sesar Ignacio A., Ares Pensado B., Castro Garcia A., Alonso Frech F., Alvarez Lopez M., et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Movement Disorders 2008, 23(8):1130-1136.
2. Tyne H.L., Parsons J., Sinnott A., Fox S.H., Fletcher N.A., Steiger M.J. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. J Neurol 2004, 251:1370-1374.
3. Pfeiffer R.F., Gutmann L., Hull K.L., Bottini P.B., Sherry J.H. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Relat Disord 2007, 13:93-100.
4. Factor S.A. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology 2004, 62(6 Suppl. 4):S12-S17.
5. Dewey R.B., Hutton J.T., LeWitt P.A., Factor S.A. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001, 58:1385-1392.
6. Trosch R.M., Silver D., Bottini P.B. Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label study. CNS Drugs 2008, 22:519-527.
7. Tomlinson C., Stowe R., Patel S., Rick C., Gray R., Clarke C. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010, 25:2649-2653.